206 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28591512	114	Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.	Glaxosmithkline
28017532	140	Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.	Astrazeneca
26652969	15	Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.	Xi'An Jiaotong University
28108251	50	Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kd inhibitors.	Bristol-Myers Squibb
28109945	25	Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.	Hangzhou Xixi Hospital
27541357	58	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.	National University Of Singapore
28105286	65	Discovery of a Potent, Selective, and Orally Available PI3Kd Inhibitor for the Treatment of Inflammatory Diseases.	RhôNe-Poulenc Rorer
27479483	61	6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors.	Csir-Indian Institute Of Integrative Medicine
27816514	103	Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties.	Novartis Institutes For Biomedical Research
27448924	53	Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.	Second Military Medical University
27994757	41	Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kd.	TBA
27994725	107	Imidazopyridazine Inhibitors of PI3Kß.	Dart Neuroscience
27765510	8	Synthesis of linear and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity.	La Trobe University
28004945	52	Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIß (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology.	Academy Of Sciences Of The Czech Republic
27391133	76	Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening.	University Of Berne
27644332	59	Class II Phosphoinositide 3-Kinases as Novel Drug Targets.	Curtin University
27774127	75	Discovery of a Series of 5,11-Dihydro-6	Dana-Farber Cancer Institute
27660692	70	Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-¿ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.	Infinity Pharmaceuticals
27186676	186	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.	West China Hospital Of Sichuan University
27217002	96	Discovery of novel 7-azaindoles as PDK1 inhibitors.	Merck
27043133	16	A Prospective Virtual Screening Study: Enriching Hit Rates and Designing Focus Libraries To Find Inhibitors of PI3Kd and PI3K¿.	Janssen Pharmaceutica
26885694	34	Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIß.	University Of California
26951753	336	Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.	Novartis Institutes For Biomedical Research
26819669	39	Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo.	Novartis Institutes For Biomedical Research
26896709	113	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.	Saarland University
26731167	32	Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.	Sun Yat-Sen University
26854431	47	Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines.	La Trobe University
26819001	29	Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.	Second Military Medical University
26774655	32	Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.	Novartis Institutes For Biomedical Research
26720154	32	(E)-1,3-diphenyl-1H-pyrazole derivatives containing O-benzyl oxime moiety as potential immunosuppressive agents: Design, synthesis, molecular docking and biological evaluation.	Anhui Agricultural University
26086931	38	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.	Shandong University
26298499	47	The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.	Amgen
26164189	21	Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Ka inhibitor with high PI3K isoform selectivity and potent cellular activity.	Novartis Institutes For Biomedical Research
26199119	135	Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.	Novartis Institutes For Biomedical Research
26210161	15	Modification of N-(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)acetamide as PI3Ks inhibitor by replacement of the acetamide group with alkylurea.	Xi'An Jiaotong University
26087940	287	Discovery of potent, selective small molecule inhibitors ofa-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIa).	Astrazeneca
26037808	75	Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Ka inhibitors.	Cairo University
25980912	41	Design of selective PI3Ka inhibitors starting from a promiscuous pan kinase scaffold.	Astrazeneca
25890697	6	Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions.	Punjabi University
26121481	37	Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase¿.	Vertex Pharmaceuticals
26005528	41	Discovery of a Potent Class of PI3Ka Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT).	Glaxosmithkline
25893045	44	Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors.	Pkucare Pharmaceutical R & D Center
25643210	16	Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.	Astrazeneca
25514658	182	Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kß and PI3Kd for the treatment of PTEN-deficient cancers.	Astrazeneca
25827523	275	Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.	Vertex Pharmaceuticals
25693787	44	6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3Ka.	Nanjing University
25666823	90	Synthesis and SAR study of potent and selective PI3Kd inhibitors.	Amgen
25415535	118	Inhibitors of c-Jun N-terminal kinases: an update.	Eberhard Karls Universit£T T£Bingen
25387153	53	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.	University Hospital Hradec Kralove
25050878	98	Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3K¿) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.	The University Of Jordan
25042253	52	Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kß inhibitors, useful as antiplatelet agents.	Astrazeneca
24992874	58	Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kß/d inhibitors for the treatment of PTEN-deficient tumours.	Astrazeneca
24881566	140	Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).	Glaxosmithkline
24754609	35	Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase¿.	Vertex Pharmaceuticals
25589920	72	Quinalozinones as Inhibitors of Class I PI3K Kinases.	Dart Neuroscience
25589915	41	Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.	Monash University (Parkville Campus)
24805946	25	Establishment of a structure-activity relationship of 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness.	Northeastern University
24560540	119	Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.	Sanofi
23944386	55	Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIa) inhibitors as anti hepatitis C (HCV) agents.	Glaxosmithkline
24387221	150	Discovery and optimization of pyrimidone indoline amide PI3Kß inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.	Sanofi
24262886	23	Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase¿ inhibitor for the treatment of inflammatory diseases.	Taisho Pharmaceutical
23855836	147	1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.	Newcastle University
23820386	32	Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.	Novartis Institutes For Biomedical Research
23726034	117	Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.	Novartis Institutes For Biomedical Research
23662903	34	Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): aß-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.	Genentech
23540645	140	Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinaseß isoform.	Genentech
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
23375793	26	Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.	Astrazeneca
24900568	27	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.	Pfizer
23410005	147	Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.	The University Of Arizona
23265896	36	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.	Monash Institute Of Pharmaceutical Sciences
23795239	62	L-Aminoacyl-triazine derivatives are isoform-selective PI3K? inhibitors that target non-conserved Asp862 of PI3K?	Monash University (Parkville Campus)
23360348	11	Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Ka.	Celgene Avilomics Research
22520259	65	Identification of ETP-46321, a potent and orally bioavailable PI3Ka,d inhibitor.	Spanish National Cancer Research Centre (Cnio)
24900504	107	Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.	TBA
22924688	128	PI3Kd and PI3K¿ as targets for autoimmune and inflammatory diseases.	Amgen
23122859	43	Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase¿ inhibitors.	Taisho Pharmaceutical
23059543	39	Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines.	La Trobe University
22832322	40	Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.	Amgen
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
23063403	21	Recent results in protein kinase inhibition for tropical diseases.	Montclair State University
22897589	100	Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.	Amgen
22877085	33	Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.	Genentech
22876881	72	Discovery and in vivo evaluation of dual PI3Kß/d inhibitors.	Amgen
23010262	46	Discovery of phosphoinositide 3-kinases (PI3K) p110ß isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.	Astrazeneca
22548365	293	Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.	Amgen
23021994	108	Identification of pyrimidine derivatives as hSMG-1 inhibitors.	Pfizer
23010274	48	Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110ß isoform inhibitors through structure-based fragment optimisation.	Astrazeneca
22548342	210	Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase¿ inhibitors.	Exelixis
22981333	103	Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.	Sanofi
22863202	94	Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.	Novartis Institutes For Biomedical Research
22819766	173	SAR studies around a series of triazolopyridines as potent and selective PI3K¿ inhibitors.	Cellzome
22524426	281	Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kß inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.	Sanofi Research & Development
22727369	6	Design, synthesis, biological evaluation and molecular modeling of novel 1,3,4-oxadiazole derivatives based on Vanillic acid as potential immunosuppressive agents.	Nanjing University
22819764	35	Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.	Spanish National Cancer Research Centre (Cnio)
22738635	87	Discovery of novel PI3K¿/d inhibitors as potential agents for inflammation.	Cellzome
22738630	76	Structure-based optimization of aminopyridines as PKC¿ inhibitors.	Vertex Pharmaceuticals
22475557	75	Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potentß isoform selective phosphatidylinositol 3-kinase inhibitors.	Glaxosmithkline
24900266	24	Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.	TBA
20138514	93	3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta.	Vertex Pharmaceuticals
20166697	71	Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.	Wyeth Research
19297156	43	Exploring the PI3K alpha and gamma binding sites with 2,6-disubstituted isonicotinic derivatives.	University Of Cincinnati
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University Of Oxford
18248814	24	Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.	Novartis Institute For Biomedical Research
17339109	33	Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.	Astellas Pharma
22361133	148	Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors.	Glaxosmithkline
22336246	7	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.	Tianjin Key Laboratory On Technologies Enabling Development Of Clinical Therapeutics And Diagnostics
22325943	71	Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.	Spanish National Cancer Research Centre (Cnio)
21985639	70	Rational design of phosphoinositide 3-kinasea inhibitors that exhibit selectivity over the phosphoinositide 3-kinaseß isoform.	Genentech
22300886	5	Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.	Nanjing University
22136433	67	7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.	Ludwig-Maximilians University Of Munich
22177407	104	Novel pyrazolo[1,5-a]pyridines as p110a-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.	University Of Auckland
22177405	104	Discovery of pyrazolo[1,5-a]pyridines as p110a-selective PI3 kinase inhibitors.	University Of Auckland
21981714	48	Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.	Genentech
21612232	113	Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.	Amgen
21925880	14	Fragment based discovery of a novel and selective PI3 kinase inhibitor.	Pfizer
21882832	116	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).	University Of Auckland
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21714526	54	Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.	Amgen
21763134	57	Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.	Pfizer
21636270	27	Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.	Genentech
21621413	24	Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability.	Dana-Farber Cancer Institute
21332118	157	Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.	Amgen
21450467	261	Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).	National Human Genome Research Institute
21341675	266	Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.	Glaxosmithkline
21322566	61	Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.	Dana-Farber Cancer Institute
21376583	232	Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.	Amgen
21353551	23	Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.	Osi Pharmaceuticals
21316229	12	Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799.	Chugai Pharmaceutical
24900252	33	Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors	TBA
21216151	66	Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements.	The Institute Of Cancer Research
21169017	63	Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening.	Astrazeneca R & D M£Lndal
21062009	70	Design, Synthesis, and Structure−Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway	TBA
21121631	28	Synthesis of phosphatidylinositol 3-kinase (PI3K) inhibitory analogues of the sponge meroterpenoid liphagal.	University Of British Columbia
21035331	32	Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.	Novartis Institutes For Biomedical Research
20860370	83	Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.	Dana-Farber Cancer Institute
20822905	28	Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.	Genentech
20797855	63	PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.	Pfizer
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
20081827	52	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.	Medical Research Council-Laboratory Of Molecular Biology
20483602	23	5-ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-alpha and mTOR for the treatment of breast cancer.	Wyeth Research
19894727	164	Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.	Wyeth Research
20346656	25	Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.	Genentech
20303263	87	Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.	Wyeth Research
20223663	100	2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.	Wyeth Research
20050669	61	Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.	Genentech
19762236	9	The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.	Kudos Pharmaceuticals
19968288	83	Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.	Wyeth Research
19969455	70	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.	Wyeth Research
19954970	64	Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.	Wyeth Research
19896845	54	Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.	Wyeth Research
18774713	66	Optimization of a series of multi-isoform PI3 kinase inhibitors.	Ucb Pharma
18644721	131	Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines.	Ucb Pharma
18625552	88	4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase.	Ucb Pharma
16789742	65	Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.	Serono Pharmaceutical Research Institute
28209465	124	Identification of highly potent and selective PI3K? inhibitors.	Bristol-Myers Squibb
28829592	109	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.	University Of Basel
28404374	81	Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.	Spanish National Cancer Research Centre (Cnio)
28541707	119	Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase? (PI3K?) Inhibitor for the Treatment of Immunological Disorders.	Bristol-Myers Squibb
28520415	91	Design and Synthesis of Soluble and Cell-Permeable PI3K? Inhibitors for Long-Acting Inhaled Administration.	Astrazeneca
28347666	45	Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3K?/? inhibitors for the treatment of PTEN-deficient tumours.	Astrazeneca
22214210	32	Synthesis and binding study of certain 6-arylalkanamides as molecular probes for cannabinoid receptor subtypes.	Cairo University
24356970	37	Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.	University Of Texas Southwestern Medical Center
14573386	17	Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.	Eli Lilly
1346637	120	Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells.	Mayo Clinic
1328199	8	Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase.	University Of Chicago
1325033	19	Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.	Universit&Acute
19090918	33	Inhibitors of tubulin assembly identified through screening a compound library.	The Ohio State University
19012568	7	Binding properties of the C-terminal domain of VIAF.	The Burnham Institute For Medical Research
18662878	12	4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.	Anadys Pharmaceuticals
19209891	34	New Insights into the Design of Inhibitors of Human S-Adenosylmethionine Decarboxylase: Studies of Adenine C(8) Substitution in Structural Analogues of S-Adenosylmethionine (dagger).	Cornell University
18817367	28	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.	Abbott Laboratories
17095227	26	Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma.	Pfizer
14722321	9	A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties.	Johnson & Johnson Pharmaceutical
18269228	93	Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.	Wyeth Research
11520201	10	X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor.	Gsk
17574423	44	Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.	Pfizer
17132624	2	Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.	Johnson & Johnson Pharmaceutical
15734645	4	Structural basis for the highly selective inhibition of MMP-13.	Aventis Pharma Deutschland
15217611	14	Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.	Vernalis (R&D)
17352464	51	Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.	Abbott Laboratories
17149864	69	Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.	University Of Massachusetts Medical School
16616489	29	Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.	Institut Curie
22552008	7	Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.	Celgene
8893827	17	Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.	Upjohn